Chronic Thromboembolic Pulmonary Hypertension: Obstruction, Surgery and Long-Term Care

CTEPH needs an experienced pulmonary vascular team to assess chronic obstruction and its treatment options. Confidence is high in that priority. New severe chest or breathing symptoms need urgent care; long-standing symptoms are not a reason to dismiss an acute change.

Table of contents

• Evidence summary: chronic obstruction needs its own pathway
• What chronic clot obstruction means
• Obstruction, small vessels and heart workload
• PEA, BPA and medicines address different parts of the problem
• What clot-clearing and circulation supplements have not established
• Persistent symptoms should lead to assessment, not assumptions
• Acute deterioration and procedure risks need clear boundaries
• Anticoagulation prevents recurrence but brings bleeding risk
• Referral should include a multidisciplinary treatment assessment
• Care continues after a successful intervention
• Clot biology does not establish treatment of chronic obstruction
• Funding and source roles
• Frequently asked questions
• Sources and funding notes

Evidence summary: chronic obstruction needs its own pathway

CTEPH is group 4 pulmonary hypertension caused by chronic thromboembolic obstruction. It differs from a new acute pulmonary embolism and from PAH. Confidence is high in the need for an experienced team to assess treatment options; this review does not independently rank surgery, devices or drugs by an audited effect size.

Chronic thromboembolic pulmonary disease, or CTEPD, can cause symptoms without pulmonary hypertension at rest. It is then distinct from CTEPH. Original classification.

What chronic clot obstruction means

After a clot, organized scar material can remain in pulmonary vessels. Persistent obstruction raises resistance and pressure, placing greater strain on the right heart. Anticoagulants help prevent further clotting but do not simply remove established fibrotic scar material. Original patient explanation.

This is not proof that every person after a pulmonary embolism develops CTEPH. Symptoms after PE have several possible explanations. Likewise, some people with chronic disease have not recognized a previous clot event. Clinical service context.

Ask which label is established: acute PE, chronic obstruction with PH, chronic disease without resting PH, or an unresolved cause of symptoms. Each label points to a different question about investigation and treatment.

Obstruction, small vessels and heart workload

The goal of evaluation is to connect the location of chronic obstruction with its effect on blood flow and right-heart workload. Ask what the individual findings establish rather than treating a scan appearance in isolation. Disease context.

Breathlessness, limited exercise, dizziness, swelling or other PH symptoms can develop. A person may compensate by doing less and underestimate the functional change. Record how familiar tasks have changed, but do not assume a symptom list supplies the diagnosis. Symptom context.

The distinction from PAH matters because an operation to remove accessible organized material targets a different problem from a drug acting on pulmonary vascular pathways. A treatment list without the diagnosis can therefore be misleading.

PEA, BPA and medicines address different parts of the problem

Pulmonary endarterectomy, or PEA, surgically removes clot/scar material in suitable patients. Suitability needs a detailed assessment of anatomy, health, risk and expert experience. A service’s average result cannot predict an individual outcome. Surgical assessment context.

Balloon pulmonary angioplasty, or BPA, is a catheter procedure used in selected patients, including those unsuitable for surgery. Papworth describes staged sessions; ask what the proposed course involves and why it fits the case. Procedure context.

Riociguat has an adult US indication for inoperable CTEPH or persistent/recurrent CTEPH after surgery. Its manufacturer label is used here for eligible context and safety, not an independent comparative treatment verdict. A medicine offer should not automatically end expert surgical assessment. Current indication.

What clot-clearing and circulation supplements have not established

No supplement is established here as a way to remove organized pulmonary obstruction, reverse CTEPH or replace prescribed anticoagulation. A claim to “thin blood” is not the same as a tested, monitored anticoagulant effect.

Do not substitute an enzyme, herb, fish oil or nitric-oxide product for the specialist plan. Laboratory fibrinolysis or vessel-relaxation findings do not demonstrate safe removal of established fibrotic obstruction in a person.

Disclose all products before starting treatment or attending a procedure. Supplements can affect other medicines and procedural safety; exact ingredients matter. Treatment of a documented nutritional need is a separate decision, not a CTEPH cure. Product safety limitations.

Persistent symptoms should lead to assessment, not assumptions

Report ongoing or new breathlessness after PE, particularly when recovery has stalled or daily function is declining. The clinician should consider chronic obstruction alongside other explanations. Neither anxiety nor an old PE diagnosis should be assumed to explain every new symptom.

Ventilation/perfusion assessment can be needed: a negative CT pulmonary angiogram does not always exclude distal chronic disease. Ask which investigation comes next. Imaging limitation.

Ask what the investigation will resolve: whether obstruction exists, whether pressure is elevated, which vessels are accessible, or whether another problem explains limitation. These are distinct questions, and a single scan may not answer them all.

Acute deterioration and procedure risks need clear boundaries

Sudden chest pain with shortness of breath, severe fainting, marked acute deterioration or coughing blood needs urgent medical assessment. Do not treat a new emergency as a routine symptom of the chronic diagnosis. Emergency warning.

PEA is major surgery. Papworth’s original consent leaflet describes bleeding, rhythm problems, confusion, neurological complications and residual pulmonary hypertension, among other risks. Ask for the individual risk/benefit discussion rather than borrowing a leaflet’s average percentage. Consent and risk context.

Ask about the risks of BPA as well as expected benefits and session number. A catheter procedure is not automatically minor or risk-free. The plan should include who handles complications and what symptoms after treatment require urgent help.

Anticoagulation prevents recurrence but brings bleeding risk

ESC/ERS recommends lifelong therapeutic anticoagulation for CTEPH; CTEPD without resting PH is individualized. Choice and monitoring require a clinician-led plan. Long-term treatment boundary.

Anticoagulants can interact with medicines, supplements and herbal products. Ask before adding a product and get an explicit plan before a procedure; do not stop treatment on your own because surgery is approaching. Interaction and procedure context.

Riociguat must not be combined with nitrates or PDE5 inhibitors such as sildenafil/tadalafil, and pregnancy is contraindicated under its label. Switching requires a prescriber-led plan. No washout duration or dose is supplied here. Current safety boundary.

Referral should include a multidisciplinary treatment assessment

Echo and right-heart catheterisation can assess cardiac effects and confirm circulation pressures within the diagnostic pathway. Additional vessel/perfusion testing informs chronic disease and intervention planning. Specialist diagnosis.

Ask whether the case has been reviewed by a service with expertise in PEA, BPA and medical treatment, and why the recommended option was selected. “Not suitable” should have an understandable reason, such as anatomy, comorbidity or expected balance of benefit and harm.

If the choice remains uncertain, an experienced multidisciplinary opinion can be useful. This is not a promise that a second opinion will change operability; it is a way to ensure that the options and their limits are clearly assessed.

Care continues after a successful intervention

A technically successful operation does not guarantee that all pulmonary hypertension disappears. Residual disease may need further care. Follow the planned symptom, imaging and circulation reassessment rather than assuming that improved breathing means monitoring can stop. Residual disease context.

Rehabilitation and activity need to fit the recovery stage and medical state. NHLBI describes supervised activity, cause-specific treatment and regular monitoring. Agree on the level of activity and the signs of deterioration that matter for this individual. Supportive care; Follow-up.

Confirm the anticoagulant plan, monitoring arrangements and the contact pathway for bleeding or recurrent symptoms. Major bleeding can require urgent help. A procedure and a preventive medicine can have complementary roles rather than one automatically replacing the other. Bleeding safety.

Clot biology does not establish treatment of chronic obstruction

An experiment affecting platelets or clot breakdown cannot establish that a product safely treats chronic organized pulmonary disease. Animal and cell findings are not used to support an efficacy verdict here.

Funding and source roles

The complete original guideline declares ESC/ERS development support without industry involvement. Separate full author declarations and ERS finances remain unresolved. ESC’s commercial income and the manufacturers behind the current labels are shown below. Government education is context, not financial clearance of its supporting trials.

Tier describes financial proximity; A–D describes credibility for the stated source role. Neither is a clinical certainty grade. Unknown finances remain unknown. Manufacturer- and sponsor-funded efficacy is excluded from the independent verdict; attributed clinical guidance is identified as guidance.

Frequently asked questions

Is CTEPH the same as a new pulmonary embolism?
No. It concerns chronic organized obstruction and pulmonary hypertension; a new acute event is a different emergency.

Do anticoagulants dissolve the scar material?
They help prevent further clotting; established fibrotic obstruction is not simply removed by anticoagulation.

Does being unsuitable for surgery mean there are no options?
No. Selected BPA and medicine options may be considered by an experienced team.

Can PH remain after PEA?
Yes. Follow-up assesses residual disease and possible further care.

Does chronic obstruction always mean CTEPH?
No. CTEPD can occur without pulmonary hypertension at rest; classification matters.

Sources and funding notes

The verified PASCAR original and development disclosure were read; author-report gaps remain. Actual Royal Papworth 2024–25 accounts notes 2–3 were checked, rather than assuming national NHS website policy applies to a separate hospital trust. Current PEA consent leaflet and BPA/service originals were opened. The current DailyMed riociguat label includes August 2026 changes; its older 2017/2021 labels were not treated as current. No universal procedural success rate, personal operative risk or drug regimen is supplied.

• ESC/ERS: complete original 2022 PH guideline — CTEPD/CTEPH distinction, perfusion assessment and long-term anticoagulation.
• Royal Papworth: PEA/CTEPH service — Organized obstruction and individual surgical suitability; service success claims not independently adopted.
• Royal Papworth: original PEA consent leaflet — Surgical purpose, bleeding/neurological risk and residual PH; no personal risk estimate.
• Royal Papworth: balloon angioplasty service — BPA purpose and staged treatment context; no cleared efficacy ranking.
• Royal Papworth: actual 2024–25 accounts — Actual trust income trace, distinct from national NHS website policy.
• NHS: PH causes, May 2023 — Chronic clot scars versus PAH and other causes.
• NHS: PH diagnosis, May 2023 — Invasive confirmation and other tests.
• NHS: PH treatment, May 2023 metadata — Cause-specific surgery and medication context.
• NHLBI: PH treatment, March 2022 — Anticoagulant/procedural role, oxygen and rehabilitation.
• NHLBI: PH symptoms, March 2022 — Breathlessness, right-heart signs and emergency warning.
• NHLBI: living with PH, March 2022 — Monitoring, activity and lifetime care.
• NHS: anticoagulants — Bleeding and clot-prevention context.
• NHS: anticoagulant considerations — Interactions/procedures; not a personalized drug selection.
• Adempas: current manufacturer label on DailyMed — Adult inoperable or persistent/recurrent postoperative CTEPH indication; contraindications only.
• ESC: institutional revenue model — ESC finance only; not an ERS audit.
• DailyMed: source of submitted labels — Label authorship/hosting distinction.
• NCCIH: supplement safety — Product interactions and limitations, not a PAH/CTEPH cure.
• NHLBI: budget and gift authority — Funding trace, not outcome evidence.
• NHS website: content and funding policy — Website funding and editorial safeguards only.
• FDA: January 2026 funding overview — Regulator finance context only.

Last reviewed: October 4, 2026. Educational information; no personal diagnosis, medication dose or supplement regimen is supplied. Local approval, product labels and clinical circumstances may differ.